Compare Citius Pharmaceuticals Inc (CTXR) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Realty Income Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Realty Income Corp trades at $54.07 (market cap $51.26B). The key difference: Realty Income Corp is far larger — about 3763.6× Citius Pharmaceuticals Inc's market cap, and Realty Income Corp pays a 6.01% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Realty Income Corp for 127 Days on average.
| CTXR | O | |
|---|---|---|
Market Cap | $13.62M | $51.26B |
Volume | 132,438 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $1.82 | $67.56 |
52-Week Low | $0.48 | $53.35 |
Typical Hold Time | 16 Days | 127 Days |
Enterprise Value | $3.79M | $81.88B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Realty Income (O) trades at $53.35, down 1.66% amid a bearish technical signal, with support at $52. The stock has missed EPS estimates for three consecutive quarters but maintains a 92.56% gross margin and 21.23% net income margin. Recent news highlights its 6% dividend yield and 136 consecutive dividend increases, though rising Treasury yields pressure REIT valuations.
The outlook is mixed: analyst consensus targets $64.80 (21% upside) with a 'Hold' bias, but debt-to-asset ratios have risen to 39.93% (2025). Key risks include interest rate sensitivity and earnings misses, while the dividend track record offers income stability. Investors face trade-offs between yield sustainability and fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
